Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Collegium PharmaceuticalCOLL -7.16%79 EV-to-EBITDA is 4.78 as of Aug. 10, 2026, which is 18% below its 10-year median of 5.86. GuruFocus rates COLL with a GF Score™ of 79/100 and a GF Value™ of $46.67 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 736 Drug Manufacturers companies, Collegium Pharmaceutical ranks better than 86.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Collegium Pharmaceutical's enterprise value is $1,854.4 Mil.
Collegium Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $387.7 Mil. Therefore, Collegium Pharmaceutical's EV-to-EBITDA for today is 4.78.
The historical rank and industry rank for Collegium Pharmaceutical's EV-to-EBITDA or its related term are showing as below:
COLL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -112.18 Med: 5.86 Max: 64.57
Current: 4.78
During the past 13 years, the highest EV-to-EBITDA of Collegium Pharmaceutical was 64.57. The lowest was -112.18. And the median was 5.86.
COLL's EV-to-EBITDA is ranked better than 86.41% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.255
vs COLL: 4.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Collegium Pharmaceutical (NAS:COLL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Collegium Pharmaceutical's PE Ratio (TTM) for today is calculated as:
Collegium Pharmaceutical's share price for today is $27.36.
Collegium Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's EV-to-EBITDA falls into.
Collegium Pharmaceutical's current Enterprise Value is $1,854.4 Mil.
Collegium Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $387.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (COLL) has a EV-to-EBITDA of 4.78 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Collegium Pharmaceutical. This is 18% below median its historical median of 5.86. According to the industry distribution chart, Collegium Pharmaceutical ranks #100 out of 736 companies in the Drug Manufacturers industry, placing it in the top 13.6%.
Is Collegium Pharmaceutical's EV-to-EBITDA too high?
Collegium Pharmaceutical's current EV-to-EBITDA of 4.78 is 18% below median its 10-year median of 5.86. The Drug Manufacturers industry median EV-to-EBITDA is 13.26. Collegium Pharmaceutical's value of 4.78 is 63.9% below this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #100 out of 736 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Collegium Pharmaceutical has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's EV-to-EBITDA compare to ETON and ALVO?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #100 out of 736 companies for EV-to-EBITDA. This places Collegium Pharmaceutical in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.26. Collegium Pharmaceutical's value of 4.78 is 63.9% below this benchmark. While the company's 10-year median is 5.86 vs. the industry median of 13.26, Collegium Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.26, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current EV-to-EBITDA of 4.78 is 63.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Collegium Pharmaceutical. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current EV-to-EBITDA is 4.78, which is 18% below median its own 10-year median of 5.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (COLL) is currently considered Possible Value Trap. The stock's GF Value™ is $46.67, compared to a current price of $27.36 — trading 41.4% below its estimated fair value. The current EV-to-EBITDA is 4.78, which is 18% below median its 10-year median of 5.86 and 63.9% below the Drug Manufacturers industry median of 13.26. Collegium Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Collegium Pharmaceutical (COLL), the current EV-to-EBITDA is 4.78 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (COLL) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of $27.36 is trading 41.4% below its estimated GF Value™ of $46.67.
GuruFocus considers Collegium Pharmaceutical to be Possible Value Trap.
Key valuation signals for COLL:
EV-to-EBITDA: 4.78 (18% below median its 10-year median of 5.86)
GF Value™: $46.67 vs. price of $27.36 (41.4% below fair value)
Industry Position: 63.9% below the Drug Manufacturers median (#100 of 736)
No single metric tells the full story. See the COLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
79GF Score
Get the complete analysis for COLL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COLL has been successfully added to your 
